Medtronic has obtained an expanded indication from the FDA for its CoreValve transcatheter aortic-valve replacement systems for use in treating severe aortic stenosis patients who are at an intermediate risk for surgery. The decision was backed by results from a 1,746-patient trial showing that, at two years, TAVR led to a lower rate of disabling stroke or all-cause mortality than surgical valve replacement.
Use of Medtronic's CoreValve TAVR systems expanded by FDA
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.